Type 2 Diabetes
Conditions
Keywords
Stress hyperglycemia ratio, Sitagliptin, Empagliflozin
Brief summary
A blood glucose level of equal to or greater than 180 mg/dL that occurred during stress in a patient without diabetes mellitus (DM) is termed stress hyperglycemia (SH). The stress hyperglycemia ratio (SHR) is defined as the fasting blood glucose divided by the blood glucose level that is calculated from the glycosylated hemoglobin (HBA1c) value on admission. A significantly higher SHR is associated with worse prognostic biomarkers in diabetic patients with complications
Detailed description
Stress hyperglycemia (SH) is an increase in circulating glucose levels in biological fluids as a physiological response to stress in diabetic patients who are known or newly diagnosed, or a pathological condition associated with in-hospital-related hyperglycemia. Interventions. Through their pleiotropic effects, some oral hypoglycemic agents improved stress hyperglycemia. When compared to non-SGLT-I (sodium glucose transporter-inhibitor) users, diabetic patients who used (SGLT-I) and had an acute myocardial infarction had less prevalent stress hyperglycemia, a smaller infarct size, and evidence of a low inflammatory response. The rationale this study is to evaluate the SHR in T2D patients who do not have serious illnesses and are managed with oral hypoglycemic agents
Interventions
DRUGSitagliptin/metformin ( 50/500mg) Oral Tablet
The drug was prescribed once daily per oral for 10 weeks
DRUGEmpagliflozin/metformin(10/500mg) Oral Tablet
The drug was prescribed once daily per oral for 10 weeks
Sponsors
University of Diyala
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
35 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥35 years * Diagnosis of Type 2 diabetes * Absence of serious illnesses * No evidence of trauma
Exclusion criteria
* Overt complications of diabetes * Any participant used antibiotics for infectious diseases * Any participant used non-steroidal antiinflammatory drugs * Current or past history of mental diseases * Current hematological diseases * Pregnancy * Nursing mothers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Stress hyperglycemia Ratio | 10 week | The ratio of stress-to-on admission blood glucose was calculated |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hematological indices | 10 week | Concentration of hemoglobin (g/dL) and the value of mean corpuscular volume (fL) |
| Inflammatory markers | 10 week | Concentration of c-reactive protein (mg/L) |
Countries
Iraq
Outcome results
None listed